Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP4010 in Relapsed or Refractory Lymphomas
NCT03119467Phase 1Terminated
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of RP4010 in lymphoma, sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2017; status: terminated.
02
Drugs
RP4010
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03119467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119467.